Cholesterol

Amgen Announces Collaboration With Two NHS Organisations to Help Improve Cholesterol Management for People at High Risk of a Heart Attack or Stroke

Retrieved on: 
Monday, October 5, 2020
Health, Clinical trials, Research, Pharmaceutical, Cardiology, Science, Lipids, Branches of biology, Metabolic disorders, Lipoproteins, Cardiology, Nutrition, Sterols, Lipid metabolism disorders, Cholesterol, High-density lipoprotein, Hypercholesterolemia, Low-density lipoprotein

Control Cholesterol: Collaborating to Reduce Risk is an innovative two-year programme adopting a quality management approach to improve health outcomes for people at high risk of a CVD event, due to raised cholesterol.

Key Points: 
  • Control Cholesterol: Collaborating to Reduce Risk is an innovative two-year programme adopting a quality management approach to improve health outcomes for people at high risk of a CVD event, due to raised cholesterol.
  • Through Control Cholesterol: Collaborating to Reduce Risk, more than 300,0004,5 people in the North West of England with potentially high cholesterol levels, will benefit from improved CVD care and cholesterol management.
  • This includes approximately 150,0004,5 who are at very high risk of having a heart attack or stroke.
  • HDL cholesterol (high density lipoprotein) carries cholesterol away from cells and back to the liver, removing cholesterol from the system.

Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator

Retrieved on: 
Thursday, October 1, 2020
Research, Diabetes, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Branches of biology, Chemical compounds, Organic compounds, Nucleotides, RTT, Adenosine monophosphate, Neurotransmitters, Purines, Thiazolidinedione, Cholesterol, Pioglitazone, MTOR, PXL770, NASH, Poxel SA

Typical risk factors for NASH include obesity, elevated levels of blood lipids (such as cholesterol and triglycerides) and diabetes.

Key Points: 
  • Typical risk factors for NASH include obesity, elevated levels of blood lipids (such as cholesterol and triglycerides) and diabetes.
  • PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH.
  • PXL065 (deuterium-stabilized R-pioglitazone), a MPC inhibitor, is in a single Phase 2 trial for the treatment of NASH.
  • Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.

Worldwide Krill Oil Industry to 2025 - Featuring Impact of COVID-19

Retrieved on: 
Tuesday, September 29, 2020
Arthropods, Ecdysozoa, Krill, Branches of biology, Dietary Supplements, Omega-3 fatty acid, Cholesterol

Being an excellent source of omega-3, krill oil helps in lowering blood pressure levels, maintaining good heart health, reducing cholesterol, and increasing metabolism.

Key Points: 
  • Being an excellent source of omega-3, krill oil helps in lowering blood pressure levels, maintaining good heart health, reducing cholesterol, and increasing metabolism.
  • The rising geriatric population coupled with the high prevalence of gastrointestinal disorders is augmenting the demand for krill oil.
  • What has been the impact of COVID-19 on the global krill oil market?
  • What is the structure of the global krill oil industry and who are the key players?

Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol

Retrieved on: 
Monday, September 28, 2020
Lipids, Medical specialties, Branches of biology, Cardiology, Lipoproteins, Low-density lipoprotein, Lipid metabolism disorders, Cholesterol, Bempedoic acid, ATP citrate lyase, Hypercholesterolemia, Statin

High levels of bad cholesterol remain an all-too-common threat for many patients.

Key Points: 
  • High levels of bad cholesterol remain an all-too-common threat for many patients.
  • In fact, 7 out of 10 people with high cholesterolin the U.S. cannot reduce their bad cholesterol down to guideline recommended levels, even with statin treatment.
  • Break the Cycle with NEXLETOL is a multichannel campaign incorporating a unique approach adapted to address new, COVID-19 driven consumer trends.
  • NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors.

Afimmune Initiates Epeleuton Phase IIb TRIAGE Study in Patients With High Triglycerides and Type 2 Diabetes

Retrieved on: 
Wednesday, September 23, 2020
Diabetes, Pharmaceutical, Health, Clinical trials, Diabetes, Clinical medicine, Organ systems, Medical specialties, Metabolic syndrome, Non-alcoholic fatty liver disease, Cholesterol, Triglyceride, Glycated hemoglobin, Hyperlipidemia, Prediabetes, Epeleuton, Afimmune

Afimmune, a clinical stage drug discovery company focused on the development of biologically active polyunsaturated lipids for the treatment of cardiometabolic diseases, announced today the start of TRIAGE (TRIglyceride And Glucose control with Epeleuton in Metabolic Syndrome Patients), a Phase IIb study of epeleuton in patients with high triglycerides and type 2 diabetes.

Key Points: 
  • Afimmune, a clinical stage drug discovery company focused on the development of biologically active polyunsaturated lipids for the treatment of cardiometabolic diseases, announced today the start of TRIAGE (TRIglyceride And Glucose control with Epeleuton in Metabolic Syndrome Patients), a Phase IIb study of epeleuton in patients with high triglycerides and type 2 diabetes.
  • In a Phase IIa study in patients with non-alcoholic fatty liver disease (NAFLD), epeleuton not only significantly lowered triglycerides and cholesterol but also statistically and clinically significantly reduced HbA1c and fasting glucose, said Dr. John Climax, CEO of Afimmune.
  • These data lead us to believe that epeleuton could be effective in metabolic syndrome patients as a first-in-class, safe and effective treatment for cardiovascular risk reduction and type 2 diabetes.
  • TRIAGE (ClinicalTrials.gov Identifier: NCT04365400 ) is a randomised, double-blind, placebo-controlled, dose finding Phase IIb study being conducted in Germany, Israel, Latvia, Switzerland and the United States to assess the efficacy and safety of orally administered epeleuton in 240 patients with hypertriglyceridemia and type 2 diabetes.

Cyclo Therapeutics to Present at 2020 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom

Retrieved on: 
Monday, September 21, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Lipid storage disorders, Rare diseases, Branches of biology, Health, Lipids, Niemann–Pick disease, type C, Niemann–Pick disease, Cholesterol, NPC, Genetic disorder, Epididymal secretory protein E1

The conference brings together patients, families, caregivers, scientists, and health professionals for the purposes of learning about advances in NPC clinical trials and providing opportunities for community learning, sharing and support.

Key Points: 
  • The conference brings together patients, families, caregivers, scientists, and health professionals for the purposes of learning about advances in NPC clinical trials and providing opportunities for community learning, sharing and support.
  • As it has for the past 5 years, Cyclo Therapeutics also provided an unrestricted grant to the NPUK to assist in support of all conference related activities.
  • Niemann-Pick Disease Type C (NPC) is a rare and fatal genetic disease affecting 1 in 100,000 live births globally.
  • NPC affects every cell in the body due to the defect in the NPC protein which is responsible for cholesterol processing in the cell.

VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia

Retrieved on: 
Monday, September 14, 2020
Health, Hospitals, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Lipids, Branches of biology, Lipid metabolism disorders, Nutrition, Sterols, Hypercholesterolemia, Low-density lipoprotein, Cholesterol

TOTUM-070 targets excess LDL-cholesterol, which is a well-known risk factor for cardiovascular disease and the main cause of atherosclerosis1.

Key Points: 
  • TOTUM-070 targets excess LDL-cholesterol, which is a well-known risk factor for cardiovascular disease and the main cause of atherosclerosis1.
  • It is believed that over 174 million adults in the US and Europe will suffer from hypercholesterolemia in 2020.
  • Obtaining this patent for TOTUM-070 in regions where populations are particularly affected by hypercholesterolemia marks a milestone in our development model aimed at building new partnerships of this scale.
  • 2 AEC Partners data for the United States and VALBIOTIS 5 priority European countries (Germany, Spain, France, Italy and the United Kingdom), 2020.

Amgen Announces Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia At ESC Congress 2020

Retrieved on: 
Saturday, August 29, 2020
Lipids, Lipid metabolism disorders, Medical specialties, Branches of biology, Familial hypercholesterolemia, Hypercholesterolemia, Statin, Low-density lipoprotein, Cholesterol, Evolocumab, Lipid profile

THOUSAND OAKS, Calif., Aug. 29, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data from the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha (evolocumab) in pediatric patients, 10-17 years of age, with heterozygous familial hypercholesterolemia (HeFH).

Key Points: 
  • THOUSAND OAKS, Calif., Aug. 29, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data from the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha (evolocumab) in pediatric patients, 10-17 years of age, with heterozygous familial hypercholesterolemia (HeFH).
  • The study showed that Repatha, in combination with statins and other lipid-lowering therapies, significantly reduced low-density lipoprotein cholesterol (LDL-C) compared to placebo.
  • These data are being presented during an oral presentation at ESC 2020 The Digital Experience, organized by the European Society of Cardiology, Aug. 29Sept.
  • This trial data gives us hope for new, safe and effective therapies for children living with familial hypercholesteremia."

Worldwide Familial Hypercholesterolemia Market to 2030 - Insight, Epidemiology and Market Forecast - ResearchAndMarkets.com

Retrieved on: 
Friday, August 28, 2020
Health, General Health, Lipid metabolism disorders, Lipids, Familial hypercholesterolemia, FH, Hypercholesterolemia, Branches of biology, Cholesterol, Health

The "Familial Hypercholesterolemia - Market Insight, Epidemiology and Market Forecast -2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Familial Hypercholesterolemia - Market Insight, Epidemiology and Market Forecast -2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Familial Hypercholesterolemia (FH) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Familial Hypercholesterolemia (FH) market size from 2017 to 2030.
  • A detailed review of Familial Hypercholesterolemia (FH) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Familial Hypercholesterolemia (FH) market.

NILEMDO® Delivers Significant Cholesterol Lowering in Addition to Statin Therapy Which is Maintained During 2.5 Years of Treatment

Retrieved on: 
Friday, August 28, 2020
Health, Clinical trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Medical specialties, Lipids, Drugs, Hepatotoxins, Statin, Low-density lipoprotein, Cholesterol, Bempedoic acid, Lipid-lowering agent, Hypercholesterolemia

This study can give our colleagues confidence that the LDL-C reductions we see with bempedoic acid are maintained over time, without a significant increase of overall adverse events on top of statins and other LLTs.

Key Points: 
  • This study can give our colleagues confidence that the LDL-C reductions we see with bempedoic acid are maintained over time, without a significant increase of overall adverse events on top of statins and other LLTs.
  • Patients enrolled in CLEAR Harmony required additional LDL-C lowering, despite receiving maximum tolerated statin therapy and other oral LLTs.
  • This years ESC Congress 2020 is a virtual experience being held online due to travel restrictions.
  • Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.